● Recruiting

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.

PhasePhase 2

Planned participants200

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoxue Pi · 0518-82342973 · Xiaoxue.pi@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07175220